| 2020 |
| 07/01 | 15:00 肝細胞がんPhase1企業治験の完了に関するお知らせ |
| 07/01 | 3,190 | 3,275 | 3,120 | 3,175 | +0.16% | 576,900 | 455億1140万 | +27.46% |
| 06/30 | 3,350 | 3,365 | 2,900 | 3,170 | -4.23% | 1,157,500 | 454億3973万 | +30.29% |
| 06/29 | 3,235 | 3,370 | 3,225 | 3,310 | +0.15% | 680,200 | 474億4653万 | +39.72% |
| 06/26 | 3,430 | 3,430 | 3,300 | 3,305 | -2.36% | 756,600 | 473億7486万 | +43.63% |
| 06/25 | 13:30 譲渡制限付株式報酬としての新株式発行に関するお知らせ |
| 06/25 | 3,365 | 3,530 | 3,250 | 3,385 | -1.46% | 2,301,300 | 485億2160万 | +51.45% |
| 06/24 | 3,335 | 3,690 | 3,255 | 3,435 | +3.15% | 3,722,700 | 492億3832万 | +58.73% |
| 06/23 | 3,750 | 3,820 | 3,305 | 3,330 | -10% | 5,680,200 | 477億3321万 | +59.33% |
| 06/22 | 2,964 | 3,700 | 2,961 | 3,700 | +23.33% | 9,481,100 | 530億3691万 | +83.26% |
| 06/19 | 13:00 COVID-19(新型コロナウイルス感染症)治療薬の開発着手について |
| 06/19 | 2,519 | 3,000 | 2,513 | 3,000 | +20% | 1,919,600 | 430億290万 | +55.52% |
| 06/18 | 2,605 | 2,623 | 2,468 | 2,500 | -4.4% | 1,747,700 | 358億3575万 | +34.05% |
| 06/17 | 2,617 | 2,800 | 2,517 | 2,615 | +12.86% | 8,426,200 | 374億8419万 | +43.6% |
| 06/16 | 2,317 | 2,317 | 2,317 | 2,317 | +20.87% | 47,500 | 332億1257万 | +30.61% |
| 06/15 | 15:00 OBP-601の新規ライセンス契約締結のお知らせ |
| 06/15 | 2,077 | 2,184 | 1,900 | 1,917 | -7.66% | 1,107,000 | 274億7885万 | +10.36% |
| 06/12 | 1,982 | 2,114 | 1,956 | 2,076 | -2.31% | 1,511,400 | 297億5800万 | +20.98% |
| 06/11 | 2,263 | 2,298 | 2,100 | 2,125 | -7.77% | 2,075,300 | 304億6038万 | +25.81% |
| 06/10 | 14:30 食道がんを対象とした放射線化学療法併用Phase1医師主導治験契約締結に関するお知らせ |
| 06/10 | 2,074 | 2,450 | 2,040 | 2,304 | +7.26% | 3,766,500 | 330億2622万 | +38.71% |
| 06/09 | 16:00 テロメライシンのハンルイ社との提携解消について |
| 06/09 | 2,050 | 2,177 | 2,007 | 2,148 | +4.93% | 1,883,100 | 307億9007万 | +32.27% |
| 06/08 | 2,099 | 2,100 | 2,003 | 2,047 | +3.07% | 1,396,300 | 293億4231万 | +28.58% |
| 06/05 | 2,018 | 2,160 | 1,967 | 1,986 | -4.79% | 4,637,900 | 284億6791万 | +26.9% |
| 06/04 | 1,992 | 2,086 | 1,941 | 2,086 | +23.72% | 5,838,600 | 299億134万 | +35.63% |
| 06/03 | 16:00 米国FDAによるテロメライシンのオーファンドラッグ指定について |
| 06/03 | 1,700 | 1,702 | 1,633 | 1,686 | -0.24% | 440,700 | 241億6762万 | +11.95% |
| 06/02 | 1,675 | 1,744 | 1,657 | 1,690 | +1.81% | 710,700 | 242億2496万 | +13.27% |
| 06/01 | 1,650 | 1,673 | 1,611 | 1,660 | +0.73% | 400,600 | 237億9493万 | +12.54% |
| 05/29 | 1,650 | 1,681 | 1,626 | 1,648 | -0.12% | 441,600 | 236億2292万 | +12.72% |
| 05/28 | 1,700 | 1,721 | 1,604 | 1,650 | -5.17% | 1,336,900 | 236億5159万 | +13.71% |
| 05/27 | 1,647 | 1,889 | 1,630 | 1,740 | +11.04% | 6,046,500 | 249億4168万 | +21% |
| 05/26 | 1,611 | 1,612 | 1,542 | 1,567 | -2.91% | 464,400 | 224億6184万 | +10.12% |
| 05/25 | 1,662 | 1,673 | 1,606 | 1,614 | -2.18% | 391,800 | 231億3556万 | +14.06% |
| 05/22 | 1,591 | 1,650 | 1,586 | 1,650 | +3.13% | 513,600 | 236億5159万 | +17.35% |
| 05/21 | 1,659 | 1,737 | 1,600 | 1,600 | +0.63% | 1,243,700 | 229億3488万 | +14.86% |
| 05/20 | 1,566 | 1,599 | 1,520 | 1,590 | +2.58% | 685,200 | 227億9153万 | +15.05% |
| 05/19 | 1,490 | 1,594 | 1,451 | 1,550 | +5.95% | 742,500 | 222億1816万 | +12.97% |
| 05/18 | 1,415 | 1,469 | 1,397 | 1,463 | +4.5% | 278,700 | 209億7108万 | +7.49% |
| 05/15 | 1,420 | 1,430 | 1,360 | 1,400 | -0.28% | 269,600 | 200億6802万 | +3.47% |
| 05/14 | 1,433 | 1,476 | 1,392 | 1,404 | -1.68% | 323,800 | 201億2535万 | +4.39% |
| 05/13 | 1,408 | 1,448 | 1,394 | 1,428 | +1.42% | 305,800 | 204億6938万 | +6.89% |
| 05/12 | 1,380 | 1,533 | 1,370 | 1,408 | +2.77% | 850,900 | 201億8269万 | +5.94% |
| 05/11 | 1,381 | 1,400 | 1,330 | 1,370 | -2.7% | 353,400 | 196億3799万 | +3.55% |
| 05/08 | 15:00 2020年12月期第1四半期決算短信〔日本基準〕(非連結) |
| 05/08 | 15:00 営業外費用の計上に関するお知らせ |
| 05/08 | 1,451 | 1,452 | 1,376 | 1,408 | -1.19% | 372,900 | 201億8269万 | +6.67% |
| 05/07 | 1,351 | 1,447 | 1,351 | 1,425 | +3.41% | 391,500 | 204億2637万 | +8.28% |
| 05/01 | 1,341 | 1,388 | 1,312 | 1,378 | +1.7% | 287,900 | 197億5266万 | +5.11% |
| 04/30 | 1,383 | 1,406 | 1,352 | 1,355 | -0.88% | 354,600 | 194億2297万 | +3.44% |
| 04/28 | 1,317 | 1,378 | 1,314 | 1,367 | +3.17% | 230,100 | 195億9498万 | +4.11% |
| 04/27 | 1,299 | 1,339 | 1,278 | 1,325 | +3.11% | 215,400 | 189億9294万 | +0.76% |
| 04/24 | 1,330 | 1,330 | 1,279 | 1,285 | -2.21% | 248,400 | 184億1957万 | -2.5% |
| 04/23 | 1,288 | 1,317 | 1,273 | 1,314 | +3.71% | 240,400 | 188億3527万 | -0.68% |
| 04/22 | 1,340 | 1,340 | 1,264 | 1,267 | -6.01% | 355,200 | 181億6155万 | -4.31% |
| 04/21 | 1,387 | 1,420 | 1,327 | 1,348 | -0.66% | 366,300 | 193億1859万 | +1.51% |
| 04/20 | 1,332 | 1,376 | 1,332 | 1,357 | +0.89% | 156,900 | 194億4757万 | +2.49% |
| 04/17 | 1,357 | 1,370 | 1,326 | 1,345 | -0.88% | 221,300 | 192億7559万 | +1.82% |
| 04/16 | 1,361 | 1,369 | 1,327 | 1,357 | -0.95% | 157,100 | 194億4757万 | +2.96% |
| 04/15 | 1,371 | 1,401 | 1,357 | 1,370 | -1.08% | 221,900 | 196億3388万 | +4.26% |
| 04/14 | 1,344 | 1,415 | 1,336 | 1,385 | +4.92% | 426,600 | 198億4885万 | +5.24% |
| 04/13 | 1,310 | 1,361 | 1,290 | 1,320 | -0.23% | 238,400 | 189億1731万 | +1.15% |
| 04/10 | 1,350 | 1,374 | 1,295 | 1,323 | -2.51% | 248,900 | 189億6030万 | +1.38% |
| 04/09 | 1,271 | 1,374 | 1,261 | 1,357 | +7.19% | 420,500 | 194億4757万 | +3.59% |
| 04/08 | 1,256 | 1,278 | 1,219 | 1,266 | +0.72% | 205,500 | 181億4342万 | -4.09% |
| 04/07 | 1,250 | 1,299 | 1,216 | 1,257 | +3.46% | 336,500 | 180億1444万 | -4.92% |
| 04/06 | 1,168 | 1,237 | 1,160 | 1,215 | +3.23% | 341,800 | 174億1252万 | -8.3% |
| 04/03 | 1,280 | 1,286 | 1,159 | 1,177 | -5.84% | 441,600 | 168億6794万 | -11.04% |
| 04/02 | 1,231 | 1,285 | 1,224 | 1,250 | +0.64% | 270,900 | 179億1412万 | -6.02% |
| 04/01 | 1,300 | 1,313 | 1,231 | 1,242 | -5.34% | 337,200 | 177億9947万 | -7.31% |
| 03/31 | 1,370 | 1,386 | 1,307 | 1,312 | +1.31% | 376,900 | 188億266万 | -3.24% |
| 03/30 | 17:15 次世代テロメライシンOBP-702の開発に向けた助成金採択に関するお知らせ |
| 03/30 | 1,260 | 1,329 | 1,258 | 1,295 | -0.69% | 320,800 | 185億5903万 | -5.61% |
| 03/27 | 1,375 | 1,394 | 1,286 | 1,304 | -4.12% | 599,100 | 186億8801万 | -6.19% |
| 03/26 | 15:00 経営体制に関するお知らせ |
| 03/26 | 1,429 | 1,462 | 1,324 | 1,360 | -5.36% | 502,200 | 194億9056万 | -3.41% |
| 03/25 | 1,448 | 1,505 | 1,409 | 1,437 | +1.34% | 702,900 | 205億9407万 | +1.05% |
| 03/24 | 1,449 | 1,459 | 1,392 | 1,418 | +1.43% | 543,900 | 203億2178万 | -1.25% |
| 03/23 | 1,371 | 1,430 | 1,341 | 1,398 | +0.07% | 388,300 | 200億3515万 | -3.65% |
| 03/19 | 16:00 海外子会社の設立に関するお知らせ |
| 03/19 | 1,408 | 1,408 | 1,310 | 1,397 | +4.8% | 413,100 | 200億2082万 | -4.84% |
| 03/18 | 1,417 | 1,482 | 1,313 | 1,333 | -3.89% | 650,400 | 191億362万 | -10.24% |
| 03/17 | 1,296 | 1,477 | 1,271 | 1,387 | +12.22% | 1,324,200 | 198億7751万 | -7.66% |
| 03/16 | 1,322 | 1,360 | 1,227 | 1,236 | -3.29% | 662,800 | 177億1348万 | -18.63% |
| 03/13 | 1,160 | 1,363 | 1,125 | 1,278 | -0.16% | 910,700 | 183億1540万 | -16.96% |
| 03/12 | 1,259 | 1,377 | 1,247 | 1,280 | +1.75% | 969,400 | 183億4406万 | -17.84% |
| 03/11 | 1,315 | 1,395 | 1,258 | 1,258 | -10.46% | 982,100 | 180億2877万 | -20.18% |
| 03/10 | 1,108 | 1,431 | 1,051 | 1,405 | +24.23% | 1,711,500 | 201億3547万 | -11.97% |
| 03/09 | 1,208 | 1,230 | 1,110 | 1,131 | -12.87% | 901,000 | 162億870万 | -29.8% |
| 03/06 | 1,418 | 1,506 | 1,276 | 1,298 | -11.46% | 1,053,000 | 186億202万 | -20.66% |
| 03/05 | 1,566 | 1,585 | 1,441 | 1,466 | -8.6% | 1,566,100 | 210億968万 | -11.58% |
| 03/04 | 1,320 | 1,604 | 1,320 | 1,604 | +23.01% | 2,223,700 | 229億8740万 | -4.41% |
| 03/04 | 7:50 中外製薬によるテロメライシン(OBP-301)の放射線併用PhaseII試験第1例目への投与開始のお知らせ |
| 03/03 | 1,411 | 1,447 | 1,283 | 1,304 | -3.48% | 650,700 | 186億8801万 | -23.02% |
| 03/02 | 1,218 | 1,458 | 1,195 | 1,351 | +16.67% | 1,371,500 | 193億6158万 | -21.54% |
| 02/28 | 1,235 | 1,302 | 1,145 | 1,158 | -14.16% | 1,399,200 | 165億9564万 | -33.49% |
| 02/27 | 1,482 | 1,512 | 1,325 | 1,349 | -10.6% | 878,600 | 193億3292万 | -23.79% |
| 02/26 | 1,613 | 1,625 | 1,454 | 1,509 | -7.37% | 813,400 | 216億2593万 | -15.7% |
| 02/25 | 1,620 | 1,690 | 1,620 | 1,629 | -5.62% | 264,500 | 233億4568万 | -9.6% |
| 02/21 | 1,718 | 1,743 | 1,718 | 1,726 | -0.4% | 98,300 | 247億3582万 | -4.64% |
| 02/20 | 1,750 | 1,762 | 1,722 | 1,733 | -1.03% | 144,400 | 248億3614万 | -4.47% |
| 02/19 | 1,714 | 1,761 | 1,711 | 1,751 | +1.8% | 178,300 | 250億9410万 | -3.69% |
| 02/18 | 1,760 | 1,782 | 1,716 | 1,720 | -3.37% | 248,600 | 246億4983万 | -5.6% |
| 02/17 | 1,770 | 1,820 | 1,739 | 1,780 | -0.73% | 235,400 | 255億971万 | -2.68% |
| 02/14 | 1,798 | 1,830 | 1,775 | 1,793 | -1.27% | 163,900 | 256億9602万 | -2.13% |
| 02/13 | 1,831 | 1,858 | 1,802 | 1,816 | -1.25% | 123,100 | 260億2564万 | -0.87% |
| 02/12 | 1,769 | 1,863 | 1,748 | 1,839 | +5.09% | 417,100 | 263億5526万 | +0.16% |
| 02/10 | 1,754 | 1,777 | 1,748 | 1,750 | -2.99% | 142,900 | 250億7977万 | -4.84% |
| 02/07 | 16:00 通期業績と前期実績との差異に関するお知らせ |
| 02/07 | 16:00 2019年12月期決算短信〔日本基準〕(非連結) |
| 02/07 | 16:00 営業外費用および特別損失の計上に関するお知らせ |
| 02/07 | 1,778 | 1,804 | 1,742 | 1,804 | +2.79% | 220,500 | 258億5366万 | -2.28% |
| 02/06 | 1,740 | 1,762 | 1,736 | 1,755 | +1.04% | 157,200 | 251億5143万 | -5.24% |
| 02/05 | 1,750 | 1,764 | 1,736 | 1,737 | -0.29% | 146,500 | 248億9346万 | -6.56% |
| 02/04 | 1,750 | 1,779 | 1,736 | 1,742 | -0.23% | 174,500 | 249億6512万 | -6.7% |
